C. Agostini et al., CD8 ALVEOLITIS IN SARCOIDOSIS - INCIDENCE, PHENOTYPIC CHARACTERISTICS, AND CLINICAL-FEATURES, The American journal of medicine, 95(5), 1993, pp. 466-472
PURPOSE: Although the accumulation of CD4 cells in the lung and other
involved tissues is regarded as the distinctive immunologic feature of
sarcoidosis, a few sarcoid patients can present with CD8 alveolitis.
This study evaluates the incidence as well as the clinical and immunol
ogic features of sarcoidosis presenting with CD8 alveolitis. PATIENTS
AND METHODS: A total of 2,214 consecutive bronchoalveolar lavage (BAL)
specimens obtained from 481 patients with sarcoidosis between January
1985 and December 1991 were retrospectively analyzed. Subjects who en
tered the study had the following characteristics: (1) lymphocyte alve
olitis and (2) lung CD4/CD8 ratio less than 1.0. Only data obtained fr
om patients with a first episode of pulmonary involvement were include
d in the analysis (394 patients). RESULTS. Fifteen of the 394 patients
studied at the time of diagnosis showed CD8 alveolitis as the present
ing manifestation; the incidence of this phenomenon was 3.8%. A follow
-up study of BAL T-cell subsets demonstrated that patients who showed
high-intensity CD8 alveolitis at the onset of the disease maintained t
he CD8 pattern of alveolitis during relapses. Phenotypic analysis of l
ung T cells revealed that the accumulation of CD8 lymphocytes was due
to the discrete local increase of CD45RO+ ''memory'' cells equipped wi
th a number of accessory structures, including adhesion molecules and
class II major histocompatibility complex-related HLA-DR antigen. CONC
LUSIONS: The accumulation of CD8 cells in the sarcoid lung is likely t
o reflect a homing of memory cells due to the ongoing immunologic resp
onse against the unknown antigen causing the disease. Although CD8 alv
eolitis can be considered a relatively rare event in sarcoidosis, the
possibility that an increase of CD8 cells in the BAL fluid might be su
stained by an underlying sarcoid inflammatory process should never be
dismissed on clinical grounds in patients with interstitial lung disea
se.